1Deucrictibant demonstrated clinically meaningful improvement in attack severity and reduced use of on-demand medication — a validated secondary endpoint outcome supporting regulatory and commercial positioning.
2The company progressed into late-stage clinical development and launch preparation with integrated oversight of CMC, global supply chain, project management, patent governance, and IT systems.
3Pharvaris relies on two contract development and manufacturing organizations (CDMOs) for deucrictibant API production — a structural safeguard against single-source supply risk.
4The 2021 Equity Incentive Plan remains central to aligning director and employee incentives with long-term value creation through product launch and commercialization.
5Market access constraints, pricing controls, and payer-driven discounting are expected to intensify — shaping future commercial strategy and reimbursement planning.
6An unexpected loss of supply or CDMO capacity could delay clinical trials or commercialization, underscoring the operational importance of supply chain resilience.